In Segment C, individuals will get ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment until illness progression or even the participants are unable to tolerate the study drugs. - "Our study unveiled the essential job on the KLF16/MYC regulatory axis in https://pauld332pak5.wikidirective.com/user